Therapeutic Area Focus

NMDA receptors are key targets for many brain and CNS disorders. Aptinyx is focused on developing novel product candidates in the areas of centralized pain, neurology, and neuropsychiatry.

Current Disease Areas of Focus

Other Relevant Disease Areas

Aptinyx - Other Disease Areas

Fibromyalgia

Fibromyalgia is a chronic condition associated with widespread pain and tenderness, as well as general fatigue. Fibromyalgia is considered by many to be a condition that is largely mediated by the central nervous system, given that fibromyalgia sufferers often present without a direct peripheral insult or injury. People suffering from fibromyalgia also often experience sleep disruption, depressed mood, and cognitive impairment. Currently, there are only three FDA-approved pharmacologic treatments for fibromyalgia, but they have limited efficacy and burdensome side effects in many patients.

Fibromyalgia
Fibromyalgia

Post-Traumatic Stress Disorder

Approximately twelve million people in the United States suffer from PTSD. PTSD results from a traumatic experience and is characterized by intrusive memories, hyperarousal, withdrawal, and negative changes in cognition, mood and sleep. PTSD can result from various forms of trauma, including combat exposure, car accidents, sexual or other physical assault, abuse, natural disasters, and others. The lifetime prevalence of PTSD is approximately seven percent in the general population but is much higher in populations at risk for exposure to trauma, such as military service members and first responders. In addition to the challenges associated with the direct symptoms, PTSD sufferers have a higher rate of suicide and often struggle with simultaneous addiction, leading to an even greater social and economic burden. Available therapeutic options are limited, including only two approved conventional SSRI antidepressants, which have limited efficacy, undesirable side effects, and target only the symptoms of PTSD, not the underlying disorder.

ptsd
ptsd

Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Cognitive impairment affects half of the approximately one million people living with Parkinson’s disease in the U.S. Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB), two forms of progressive dementia that lead to a decline in a broad spectrum of cognitive and functional abilities, comprise 15 to 25% of newly diagnosed dementia patients.

Both Parkinson’s disease and dementia with Lewy bodies share a common disease pathology, believed to be caused by increased levels of alpha synuclein in the brain. Increased alpha synuclein levels has been associated with reductions in NMDA receptor expression and activity. Given the importance of NMDA receptor activity on cognition, memory, and learning, we believe NYX-458 – through enhancing NMDA receptor activity – has the potential to address declines in cognitive function in these patients.